IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
- by Kelsey Overberg
- Dec 4, 2019
Full story: Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis
Analysis of fibroblast migration dynamics in idiopathic pulmonary fibrosis using image-based scaffolds of the lung extracellular matrix
- by Marisa Tisler, Samuel Alkmin, Hsin-Yu Chang, Jon Leet, Ksenija Bernau, Nathan Sandbo, and Paul J. Campagnola
- Dec 4, 2019
Full story: Analysis of fibroblast migration dynamics in idiopathic pulmonary fibrosis using image-based scaffolds of the lung extracellular matrix
Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
- by Kelsey Overberg
- Dec 3, 2019
Full story: Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019
Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
- by Kelsey Overberg
- Nov 20, 2019
Full story: Promedior Enters Into Definitive Merger Agreement To Be Acquired By Roche
Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
- by Kelsey Overberg
- Nov 20, 2019
Full story: Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965
FDA Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
- by Karalyne Rubino
- Oct 3, 2019
Full story: FDA Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
- by Steven Greenberg, Gerald Horan, Brydon Bennett, Kate Blease, Ying Ye, Ada Azaryan, Francisco Ramirez-Valle, Ralph Ceres, Peter Schafer
- Oct 3, 2019
Full story: Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
- by Karalyne Rubino
- Oct 3, 2019
Full story: Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Gilead and Galapagos enter into transformative research and development collaboration
- by Karalyne Rubino
- Oct 3, 2019
Full story: Gilead and Galapagos enter into transformative research and development collaboration
Galecto Biotech's lead molecule TD139 is safe, well tolerated, with direct target engagement and biomarker effects in a clinical Phase 1b/2a trial in IPF patients
- by Karalyne Rubino
- Oct 3, 2019
Full story: Galecto Biotech's lead molecule TD139 is safe, well tolerated, with direct target engagement and biomarker effects in a clinical Phase 1b/2a trial in IPF patients
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
- by Karalyne Rubino
- Oct 3, 2019
Full story: FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
Breath Therapeutics announces initiation of global Phase 3 trials for the treatment of bronchiolitis obliterans syndrome
- by Karalyne Rubino
- Oct 3, 2019
Full story: Breath Therapeutics announces initiation of global Phase 3 trials for the treatment of bronchiolitis obliterans syndrome
BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
- by Karalyne Rubino
- Oct 3, 2019
Full story: BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
IND application of ND-L02-s0201 allowed to proceed for idiopathic pulmonary fibrosis indication by the FDA
- by Karalyne Rubino
- Oct 3, 2019
Full story: IND application of ND-L02-s0201 allowed to proceed for idiopathic pulmonary fibrosis indication by the FDA
Galapagos announces ISABELA Phase 3 program in IPF
- by Karalyne Rubino
- Oct 3, 2019
Full story: Galapagos announces ISABELA Phase 3 program in IPF
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
- by Karalyne Rubino
- Oct 3, 2019
Full story: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
- by Karalyne Rubino
- Oct 3, 2019
Full story: Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
- by Karalyne Rubino
- Oct 3, 2019
Full story: Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
FDA Approves Boehringer Ingelheim’s OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
- by Karalyne Rubino
- Oct 3, 2019
Full story: FDA Approves Boehringer Ingelheim’s OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
- by Karalyne Rubino
- Oct 3, 2019
Full story: New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.